Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by kingposton Feb 01, 2015 1:39pm
266 Views
Post# 23386469

RE:Generics co Ani Pharm SP goes from $6.00 to $55 in a yr

RE:Generics co Ani Pharm SP goes from $6.00 to $55 in a yrAni 's rapid browth from a startup to about $1 Billion CDN market cap, in just over a year, was done on the back of deal making in the generics space --- both traditional and specialty generics... It underscores the massive opportunities for deal making in the  generics sector now, and also my view that NPH's existing portfolia is just a start, and gives them the platform and credibility, to successfully pursue strategic deals for NPH... BTW Ani has something in common with another company I talked about, Akorn  Pharma, since Ani recently got Akorns past CEO.. I think it will be even easier for NPH to land deals , than Like for ANI, since the US market is the golden plam of markets and always is in high demand...Generics in Canada is right now an undiscovered gem, off the radar a bit, and so rights in many cases will be given away for free , or very cheap... yes you heard that corect.. the secrt is in the deal making...and I want NPH to be a talented dealmaker...and everything is fitting into place..
Bullboard Posts